Aethlon Medical (NASDAQ:AEMD), has announced that the Medanta Institutional Ethics Committee (MIEC) has granted full ethics approval for a safety, feasibility, and dose finding study of its Hemopurifier in cancer...
Aethlon Medical (NASDAQ:AEMD) appointed Charles Fisher, M.D., as CEO, effective Oct. 30. Dr. Fisher joined Aethlon as a member of its board and served as its chairman since November 2017. He succeeds Dr. Timothy Rodell...
By Len Zehr Aethlon Medical (OTCQB:AEMD), sporting FDA approval of an investigational drug exemption (IDE), plans to begin treating patients infected with hepatitis C virus (HCV) early next year in a feasibility study...